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Abstract
Most patients with tuberous sclerosis complex (TSC) develop cortical tubers that cause severe neurological
disabilities. It has been suggested that defects in neuronal differentiation and/or migration underlie the appearance
of tubers. However, the precise molecular alterations remain largely unknown. Here, by combining cytological and
immunohistochemical analyses of tubers from nine TSC patients (four of them diagnosed with TSC2 germline
mutations), we show that alteration of microtubule biology through ROCK2 signalling contributes to TSC
neuropathology. All tubers showed a larger number of binucleated neurons than expected relative to control
cortex. An excess of normal and altered cytokinetic figures was also commonly observed. Analysis of centrosomal
markers suggested increased microtubule nucleation capacity, which was supported by the analysis of an expression
dataset from cortical tubers and control cortex, and subsequently linked to under-expression of Rho-associated
coiled-coil containing kinase 2 (ROCK2). Thus, augmented microtubule nucleation capacity was observed in mouse
embryonic fibroblasts and human fibroblasts deficient in the Tsc2/TSC2 gene product, tuberin. Consistent with
ROCK2 under-expression, microtubule acetylation was found to be increased with tuberin deficiency; this alteration
was abrogated by rapamycin treatment and mimicked by HDAC6 inhibition. Together, the results of this study
support the hypothesis that loss of TSC2 expression can alter microtubule organization and dynamics, which, in
turn, deregulate cell division and potentially impair neuronal differentiation.
Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Keywords: cytokinesis; microtubule; ROCK2; TSC2; tuberous sclerosis complex
Received 17 September 2013; Revised 20 January 2014; Accepted 28 February 2014
No conflicts of interest were declared.
Introduction
Heterozygous loss-of-function mutations in the tumour
suppressor genes TSC1 and TSC2 cause the autosomal
dominant disorder tuberous sclerosis (TSC) [1]. TSC
patients present multi-system pathology characterized
by abnormal cell growth and proliferation. Cortical
tubers are present in > 80% of patients and are mani-
fested by the presence of dysplastic neurons, glial cells
and glioneuronal giant cells, which together disrupt
the laminar architecture of the cortex [2]. As a result,
TSC patients often suffer from severe epilepsy, mental
retardation, autism and/or attention deficit hyperactivity
disorder [3].
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Hamartin and tuberin, the respective products of the
TSC1 and TSC2 genes, form a heterodimer that inhibits
the mechanistic target of rapamycin (mTOR) complex
1 (mTORC1) [4]. Mutations in TSC1 or TSC2 lead
to an increase in the activity of the RAS homologue
enriched in brain (RHEB), which, in turn, activates
mTORC1 [4]. Downstream targets of mTORC1 include
the ribosomal protein S6 kinase and the eukaryotic
translation initiation factor 4E binding protein 1 [4].
The hamartin–tuberin heterodimer also activates mTOR
complex 2 (mTORC2), which positively regulates the
actin cytoskeleton [4].
It has been proposed that the neurological alterations
of TSC are caused by defects in neuronal differentiation
and/or migration [5,6]. Depletion of hamartin or tuberin
in mice was shown to induce ectopic axons and promote
axon growth, leading to perturbed neuronal polarity
[7]. More recent studies that examined the phenotypic
consequences of hamartin or tuberin depletion in neu-
ronal cell types, including neuronal stem cells, have
further suggested defects in polarity, differentiation
and/or migration [8–11]. In addition, studies of differ-
ent cell types have linked loss of function of hamartin
or tuberin to defects in primary cilium formation, cell
polarity and division [12–16]. This array of cellular
defects may indicate a deregulation of the microtubule
cytoskeleton and/or its organization and assembly at the
centrosome, the major microtubule-organizing centre in
dividing animal cells. Moreover, hamartin was previ-
ously shown to physically interact with polo-like kinase
1 (PLK1) [13], a key kinase regulator in microtubule
assembly, while tuberin functionally associates with the
microtubule-associated protein TACC3 in maintaining
the integrity of the mitotic spindle and nuclear enve-
lope [12]. To date, however, detailed examination of
microtubule-centred cellular and molecular alterations
is lacking in TSC.
Materials and methods
Tissue and genetic analyses
Brain tissues from three unrelated controls and
nine TSC patients were obtained at the Institute of
Neuropathology (University Hospital Bellvitge, IDI-
BELL, L’Hospitalet del Llobregat, Barcelona) and
at the Epilepsy Unit of the Teknon Medical Centre
(Barcelona). Participants provided written informed
consent and the study was approved by the IDIBELL’s
ethics committee. All clinical investigation was con-
ducted according to the principles expressed in the
Declaration of Helsinki. Tissues were obtained at
surgery, fixed in 10% buffered formalin and processed
for paraffin sections. Sections were stained with haema-
toxylin and eosin (H&E), following a standard protocol,
and histopathologically diagnosed at the Institute of
Neuropathology. Genetic analyses were performed at
the Centre for Molecular Diagnostics of Neurological
Diseases of the Universidad Complutense (Madrid) and
at the Department of Clinical Genetics of the Erasmus
Medical Centre (Rotterdam).
Antibodies, small molecules
and immunohistochemistry
The antibodies used in this study were: anti-centriolar
coiled-coil protein, 110 kDa (CP110) [17];
anti-nucleoporin, 62 kDa (NUP62; clone 53, BD
Transduction Laboratories); anti-PLK1 (clone 208G4,
Cell Signaling Technology); anti-phospho-Ser235-236
S6 ribosomal protein (pS6; clone 91B2, Cell Signaling
Technology); anti-ROCK2 (clone 21, BD Transduction
Laboratories); anti-TACC3 (H-300, Santa Cruz Biotech-
nology); anti-α-tubulin (TUBA; ab44928, Abcam);
anti-acetylated tubulin (acTUB; clone 6-11B-1, Sigma
Aldrich); and anti-γ-tubulin (TUBG1; clone GTU-88,
Sigma-Aldrich). Rapamycin (allosteric mTOR inhibitor,
purchased from Sigma-Aldrich) and CAY10603
(HDAC6-specific inhibitor, purchased from Santa Cruz
Biotechnology) were added to cell cultures at 44 and 2
nM, respectively, for 16 h prior to analysis ofmicrotubule
acetylation levels. Immunohistochemical analyses were
performed on serial paraffin sections, 4 μm thick, using
the Envision method (Dako). The antibody dilutions
and antigen retrieval-based solutions (dilution/solution)
were: 1:1000/EDTA, 1:300/EDTA, 1:100/sodium cit-
rate, 1:500/sodium citrate, 1:300/EDTA, 1:300/sodium
citrate and 1:1000/EDTA for anti-CP110, anti-NUP62,
anti-PLK1, anti-pS6, anti-ROCK2, anti-TACC3 and
anti-TUBG1, respectively. Endogenous peroxidase was
blocked by pre-incubation in a solution of 3% H2O2,
and blocking was performed in 1× phosphate-buffered
saline (PBS) with 5% goat serum or 1% bovine serum
albumin (BSA) and 0.1% Tween 20 (Sigma-Aldrich).
The sections were lightly counterstained with haema-
toxylin (except for anti-NUP62, to allow nuclei
assessment), and examined with an Olympus BX51
microscope. Detection of ROCK2 was carried out
using the DAB-nickel method. The specificity of the
anti-TUBG1 antibody in paraffin sections was assessed
previously [18]. The expected immunostaining pattern
of this centrosomal marker in normal cells is one or two
foci proximal to the nucleus; nonetheless, its expression
in differentiated cells can be low and, thus, hamper the
identification of centrosomes. Each tissue sample and
marker was evaluated in at least two independent assays
and no substantial intratissue difference was observed.
For seven TSC tissue samples, equivalent sections were
processed to include incubation with a non-immune
murine immunoglobulin control, which did not reveal
staining in any case. Two investigators carried out
quantification of binucleated cells, and cytokinetic
figures and abnormalities, independently. Statistical
significance was assessed using quadruplicate measures
and contingency tables with the Fisher’s exact test.
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Silencing of endogenous TSC2 expression
and rescue experiments
The short hairpin (sh) RNA against TSC2 expression
(Sigma-Aldrich; for sequence, see supplementary
material, Table S1), control non-hairpin pLKO.1 and
lentivirus packaging plasmids (Addgene) were as pre-
viously described [12]. Transduced cells were selected
with 0.5 μg/ml puromycin (GIBCO) and maintained
with 0.3 μg/ml puromycin. The assays assessing the
consequences of shRNA-mediated silencing of TSC2
expression in fibroblasts represented a pooled popula-
tion of puromycin-resistant cells. The small interfering
(si) RNAs against TSC2 expression (Dharmacon; for
sequence, see supplementary material, Table S1) and
control scrambled siRNA were transfected into cells as
previously described [19]. For the reconstitution assays,
cells were transiently transfected with GFP–TSC2,
GFP–TSC2 and TSC1–His or GFP-alone expression
constructs, using Lipofectamine. Cellular phenotypes
were measured in GFP-positive cells.
Quantitative reverse transcriptase–polymerase
chain reaction
RNA extraction from human BJ fibroblasts and
sub-lines, and quantitative reverse transcription–
polymerase chain reactions (qRT–PCRs) were per-
formed as described previously [19]. The primers
used in these assays are detailed in Table S1 (see
supplementary material).
Microtubule regrowth assay and acetylation
analysis
The Tsc2+/+/Tp53−/− and Tsc2−/−/Tp53−/− mouse
embryonic fibroblasts (MEFs) and the human foreskin
BJ fibroblasts (ATCC) and sub-lines were cultured
following standard protocols. Cells growing on cov-
erslips were treated with 1 μM nocodazole at 37∘C
for 16 h, followed by drug washout and incubation
on ice (cold medium) for 1 h. Cells were then recov-
ered in pre-warmed growth medium at 37∘C to allow
microtubule regrowth, and subsequently fixed (in cold
methanol) at various time points for immunostaining of
TUBA. Microtubule regrowth was analysed in mitotic
cells, as indicated by DNA condensation. Microtubule
asters were quantified using maximal projections
derived from ImageJ (National Institutes of Health,
Bethesda, MD, USA). For analysis of acetylated tubulin
(acTUB), cells growing on coverslips were stained for
acTUB and total tubulin (TUBA) and counterstained
with DAPI. Confocal images were acquired and the
levels of acTUB were normalized to the intensity of
TUBA, using FV10-ASW software.
Gene set expression analysis
Preprocessed and normalized microarray data for con-
trol cortex and cortical tubers were obtained from
the Gene Expression Omnibus reference GSE16969
[20]. This dataset included gene expression analysis
for tissues from four normal cortex and four cortical
tubers (two cases with a mutation in TSC1 and two
cases with a mutation in TSC2) [20]. The distribution of
Gene Ontology (GO) [21] gene sets in whole-genome
ranked GSE16969 results was examined using the gene
set expression analysis (GSEA) [22] tool, with default
values for all parameters. This analysis assessed the bias
in the distribution of each GO term (linked to genes) in
the whole-genome ranking of average gene expression
differences between the cortical tuber and normal cortex
tissue.
Results
Binucleated neurons in tubers
Cortical tubers from nine TSC patients and cortex tis-
sue from three unrelated healthy individuals were exam-
ined in this study. Patients were clinically diagnosed
with TSC following consensus diagnostic criteria. As
part of their clinical evaluation, four patients were iden-
tified as carrying heterozygous germline mutations in
TSC2; the remaining three were not characterized at the
genetic level (see supplementary material, Table S2).
According to the diagnoses, all tubers showed the clas-
sic histopathological features of TSC, which include
disorganization of the cortical layer, increased astro-
cytic gliosis and the presence of large binucleated cells
(Figure 1A; see also supplementarymaterial, Figure S1).
Quantification of binucleated cells revealed a signifi-
cantly higher percentage in all tubers relative to con-
trols (Fisher’s exact test p values < 0.01; Figure 1B).
This observation is consistent with previous neurohis-
tological studies [2] and with cellular analyses of MEFs
deficient in tuberin [12]. Hamartin deficiency was also
previously linked to an increase in binucleated MEFs
[12]. As expected, enhanced activation of mTORC1 sig-
nalling (revealed by pS6 staining) was detected in all
tubers examined in this study and was particularly evi-
dent in giant cells (Figure 1A; see also supplementary
material, Figure S1).
Cytokinesis alteration in tubers
Among the potential defects in cell division, failure
of cytokinesis may be the cause of the binucleated
cells [23]. Previously, deficiency of hamartin or tuberin
in MEFs was also linked to a delay in completion of
cytokinesis and, by extension, to aberrant abscissions
[12]. Frequent cytokinesis failure was also observed
in cell lines derived from skin angiofibromas of TSC
patients [24]. Therefore, we subsequently examined
H&E-stained cortical tuber sections for the propor-
tion of cytokinetic figures and potential associated
alterations. All tubers revealed a higher number of
cytokinetic figures (most of them apparently aberrant)
than expected, relative to control tissue (Figure 2A,
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Figure 1. Binucleated cells and pS6 positivity in cortical tubers. (A) Representative images of H&E staining (left and middle panels) and pS6
immunostaining (right panels) in a control cortex and in a TSC tuber (images for all tubers are provided in Figure S1). A black-filled arrow
indicates a binucleated cell and a red-filled arrow indicates cellular pS6 positivity; scale bars = (left) 400 μm; (middle) 200 μm; (right) 300
μm. (B) Quantification (represented as percentage) of binucleated cells in the control sample and tubers. The results correspond to four
randomly chosen fields with at least 50 cells in each, examined in each sample; error bars show SD for the measured fields
quantification provided in panel 2B; see also supple-
mentary material, Figure S2); consequently, aberrantly
shaped nuclei were frequently observed (Figure S2).
Next, immunohistochemical detection of the nucleo-
porin NUP62 confirmed the presence of cytokinetic
abnormalities (Figure 2C shows representative images
of control and tuber tissue).
Alteration of TUBG1 in tubers
Cytokinesis failure may be the consequence or cause of
abnormal centrosome numbers, structure and/or position
[25]. Hamartin or tuberin deficiency has been linked to
alterations of the centrosome, such as amplification in
hamartin-deficient cells [13], and of centrosome-related
organelles, such as disrupted primary cilia in hamartin-
or tuberin-deficient cells [14–16]. On the basis of these
observations, the abundance of TUBG1 and the num-
bers of TUBG1-positive foci (ie potential centrosomes)
were evaluated by immunohistochemistry in the tubers.
While the majority of cells in control tissues contained
one or two signals/cell, which would represent a nor-
mal complement of centrosomes, a variety of abnormal-
ities were observed in the tubers, including potential
centrosome amplification, fragmentation and hypertro-
phy, with TUBG1 over-expression revealed in all cases
(Figure 3A; see also supplementary material, Figures
S3, S4). Quantification indicated a higher number of
abnormalities in the tubers than in the controls: all tubers
contained > 40% of cells with TUBG1-related abnor-
malities (Figure 3B).
We next examined whether the excess TUBG1
immunoreactivity was associated with numerical
changes to centriole numbers, which might indicate
dysfunction in the control of centrosome duplica-
tion [17]. Interestingly, the levels and localization of
the centriolar marker CP110 were not substantially
altered in any of the tubers relative to the controls
(Figure 3C shows representative images with defined
centriolar signals). Taken together, cytological and
immunohistochemical studies in tubers from nine TSC
patients revealed frequent binucleated cells, cytokinetic
abnormalities and augmented TUBG1 abundance
without centriole duplication.
Deregulation of proteins involved
in microtubule-based processes
To gain insight into a putative mechanism,
whole-genome expression data from cortical tubers
and normal cortex [20] were analysed. Consistent with
our findings of an excess of binucleated cells (Figure 1)
and cytokinetic figures (Figure 2) in tubers, the analysis
of genes annotated with the GO term ’Cytokinesis’
(genes, n = 47) showed a significant difference in
absolute expression values (ie considering expres-
sion changes independently of their sign) between
tubers and normal cortex (p = 0.038; Figure 4A). The
difference was not significant when real expression
values (ie considering the direction of the expression
difference, positive or negative) were examined, but
an under-expression trend was observed in tubers for
genes required for the completion of cytokinesis; the
most under-expressed gene in this setting was ROCK2
(Figure 4B).
The under-expression of ROCK2 was of particular
interest, given its depicted role in the regulation of
Copyright © 2014 Pathological Society of Great Britain and Ireland. J Pathol 2014; 233: 247–257
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
Microtubule abnormalities in tuberous sclerosis lesions 251
Figure 2. Cytokinesis defects in cortical tubers. (A) Representative images of H&E-stained control cortex and TSC tuber tissue; arrows
indicate cytokinetic figures or alterations in the tuber (images for all tubers are provided in Figure S2, see supplementary material); scale
bar = 100 μm. (B) Quantification (%) of cytokinetic figures in the control sample and tubers. Results correspond to four randomly-chosen
fields examined in each sample; error bars show SD for the measured fields. (C) NUP62 immunostaining in control cortex and TSC tuber
tissue; abnormal cytokinetic figures in the tuber are indicated by arrows; scale bar = 50 μm
microtubule assembly [26,27] as well as in the acto-
myosin ring contraction required for cleavage furrow
ingression and cytokinesis [28,29]. Next, immunohisto-
chemical analyses of ROCK2 in our tissue set confirmed
its under-expression and association with loss of laminar
architecture in the tubers (Figure 4C; see also supple-
mentary material, Figure S5). In addition, the ROCK2
substrate tubulin polymerization-promoting protein 1
(TPPP1) was also suggested to be under-expressed in
the analysis of the gene expression dataset (two-tailed
t-test, p = 0.04). The analysis of a gene set corre-
sponding to curated centrosomal proteins [30] also sug-
gested an association with the neuropathology: there
was a trend for over-expression of centrosomal genes in
tubers relative to normal cortex (real differences GSEA
p = 0.022; and absolute differences GSEA p = 0.046).
This association with over-expression of centrosomal
gene products may be a consequence of increased cell
proliferation, as observed for different malignant neo-
plasms [31]. Intriguingly, while PLK1 and TACC3 did
not contribute to this bias (ie none of their microarray
probes showed evidence of differential expression; this
was confirmed by immunohistochemistry, not shown),
the two probes corresponding to chTOG, which encodes
for a key microtubule-binding and TACC-interacting
protein [32], indicated significant under-expression in
the tubers (two-tailed t-test, p< 0.01). According to pre-
vious reports [32], loss of chTOG expressionmay impair
microtubule biology and alter cytokinesis. Together,
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Figure 3. Over-expression and abnormal staining patterns of TUBG1 in cortical tubers. (A) Representative images of TUBG1 immunoreactivity
in a control cortex, which shows cytoplasmic staining (top panels), and in TSC tubers (images for all tubers are provided in Figure S3, see
supplementary material); arrows indicate abnormal staining or alteration in the expected centrosome number; scale bars = (left) 400 μm;
(right) 50 μm. (B) Quantification (represented as absolute number, n) of TUBG1-based signals that could represent centrosomes; the results
correspond to at least 200 cells counted in each sample. (C) Representative images of CP110 immunostaining in control cortex and TSC
tuber tissue; scale bar = 200 μm
these observations further suggest an underlying alter-
ation of microtubule biology in TSC neuropathology
and, specifically, point to loss of ROCK2 function as a
critical factor in this context.
Increased microtubule regrowth with deficiency
of tuberin
To test our hypothesis that loss of TSC2 expression
leads to increased microtubule regrowth capacity,
we first examined a murine cell model of tuberin
deficiency, within which we previously character-
ized abscission alterations and increased frequency of
binucleated cells [12]. In synchronous G2/M popula-
tions of Tsc2+/+/Tp53−/− and Tsc2−/−/Tp53−/− MEFs,
quantitation of microtubule regrowth (ie the length of
microtubules in asters) was found to be significantly
greater in tuberin-deficient MEFs than in controls
(t-test, p < 0.05; Figure 5A, B).
Next, we established stable sub-lines of human
BJ fibroblasts with lentivirus-mediated transduc-
tion of a shRNA targeting TSC2 expression or a
non-hairpin-negative shRNA control. A significant
reduction in the levels of TSC2 expression was achieved
(Figure 6A, B), and this depletion was associated with
augmented microtubule regrowth capacity in mitotic
cells relative to the control, non-hairpin-treated and
untreated control cells (Figure 6C, D). Importantly,
we did not observe alterations of the nuclear envelope
(as previously reported in MEFs [12]) or gross cen-
trosome abnormalities in non-mitotic tuberin-depleted
cells (see supplementary material, Figure S6). Next,
we confirmed that augmented microtubule regrowth
capacity was the result of the specific loss of TSC2
expression through two complementary approaches:
using siRNAs that supported transient loss of TSC2
expression (see supplementary material, Figure S7A,
B); and through reconstitution of tuberin expression
using transient transfection of a GFP-TSC2 construct,
alone or in combination with exogenous hamartin–His
(see supplementary material, Figure S7C), which was
revealed to be sufficient to recover aster lengths to the
levels observed in control shRNA-treated cells (see
supplementary material, Figure S7D). Thus, the loss of
tuberin expression is sufficient to augment microtubule
regrowth capacity, but the mechanism responsible for
this effect is not yet clear.
Under-expression of ROCK2 and increased
microtubule acetylation
In tubers relative to normal cortex, both ROCK2 and
TPPP1 were predicted to be under-expressed (Figure 4,
confirmed for ROCK2 by immunohistochemistry;
see also supplementary material, Figure S5). At the
molecular level, ROCK2 activity regulates microtubule
polymerization through TPPP1 and acetylation through
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Figure 4. Expression alterations linked to cytokinesis and microtubule-based processes and proteins. (A) Graph showing the GSEA output
for the GO ’Cytokinesis’ gene set. The enrichment score is shown on the y axis and the gene positions on the x axis, which correspond to
the expression differences (in absolute values and taking the maximum difference if > 1 microarray probes exist for a given gene) between
the tuber and normal cortex tissue [20]. The computed p value relative to the enrichment score is shown. (B) Graph showing the GSEA
output for the GO ’Cytokinesis’ gene set, as above, but ranking expression differences with real values (from positive, which corresponds
to higher expression in tubers, to negative, which corresponds to higher expression in normal cortex). (C) Representative images of ROCK2
immunoreactivity in control cortex and TSC tuber tissue (images for all tubers are provided in Figure S5, see supplementary material). The
DAB-nickel (blue) method was used in immunodetection; scale bars = (left) 400 μm; (right) 200 μm
HDAC6 [26,27]. Next, we investigated the expres-
sion of ROCK2 and found it significantly reduced
in tuberin-depleted BJ fibroblasts, as measured by
qRT–PCR (Figure 7A) and western blot analysis
(Figure 7B). Subsequently, microtubule acetylation
relative to the total intensity of microtubule immunoflu-
orescence was examined for phenotypic evidence of
deregulation of the corresponding signalling pathway.
Thus, the levels of acTUBwere found to be significantly
elevated in tuberin-depleted BJ fibroblasts (Figure 7C,
D; see also supplementary material, Figure S8A) and
rescue through expression of GFP–tuberin significantly
reduced acTUB levels in these cells (see supplementary
material, Figure S8B).
Tuberin mutation or depletion leads to an increase
in mTORC1 activity [4], so levels of acTUB were
subsequently assessed using the mTORC1 inhibitor
rapamycin. Exposure to this compound was sufficient
to normalize acTUB in tuberin-depleted BJ fibrob-
lasts (Figure 7E). Conversely, the treatment of control
cell cultures with a small-molecule-specific HDAC6
inhibitor (CAY10603) was sufficient to elevate acTUB,
but the levels of acetylation were not further augmented
in tuberin-depleted cells treated with this inhibitor
(Figure 7E). Taken together, these data depict a model
in which loss of TSC2 expression is sufficient to alter
microtubule biology through attenuation of ROCK2 sig-
nalling, which culminates in the inhibition of HDAC6
and microtubule acetylation.
Discussion
In most current models of TSC pathology, loss of tuberin
or hamartin results in defects in neuronal migration
and differentiation [7–9,12], processes that are expected
to be reliant on appropriate microtubule biology [33].
Here, examination of cortical tubers from nine TSC
patients suggested that the neuropathology is linked to
aberrant microtubule biology, as seen by the increased
abundance of binucleated cells, cytokinetic figures and
TUBG1 abundance by immunohistochemistry. Gene
expression analyses in tubers, as well as in human
tuberin-depleted fibroblasts, revealed decreased expres-
sion of key components of microtubule biology, partic-
ularly of ROCK2. Human tuberin-depleted fibroblasts
displayed the expected outcome of diminished ROCK2
expression and increased microtubule acetylation. Thus,
attenuated ROCK2 signalling might represent a tar-
getable mechanism for the treatment of TSC tubers.
However, given the relatively small sample size in our
study, the depicted histopathological alterations may
warrant confirmation in larger series of TSC patients.
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Figure 5. Increased microtubule regrowth capacity in
tuberin-deficient MEFs. (A) TUBA immunostaining images
for 6 min time points in tuberin-wild-type and -deficient MEFs;
scale bar = 10 μm. (B) Quantification of microtubule aster
projections in the presence of nocodazole (time = 0 min) and after
release for 3 and 6 min, respectively (at least 10 cells counted
in each condition; *p < 0.05; and error bars show SD for the
measured cells)
The Rho family of small GTPases is involved in sev-
eral fundamental cellular processes, such as prolifer-
ation and motility [34]. ROCK2 is a serine/threonine
kinase that is highly expressed in brain and regulates
actin and microtubule dynamics [34]. Thus, ROCK2
plays a key role in cell migration, differentiation and
mitotic phases such as cytokinesis [34,35]. Consistent
with these observations, decreased ROCK2 expression
has been correlated with aberrant cytokinesis in pre-
vious studies [28]. While ROCK2 is usually found in
the cytoplasm, it also co-localizes with PLK1 at the
cleavage furrow during cytokinesis [28]. Indeed, in vitro
studies have suggested that PLK1 phosphorylates and
activates ROCK2 to regulate the actomyosin ring con-
traction that is required for cleavage furrow ingression
during cytokinesis [28]. Thus, PLK1 and TACC3 may
not have a direct role in the neuropathology of TSC, but
their effectors and/or regulators (ROCK2, as shown in
this study, and chTOG) are proposed to be altered in
tuber development. Collectively, decreased expression
of ROCK2 downstream of loss of tuberin has the poten-
tial to disrupt mitosis and induce binucleated cells. How-
ever, unlike the cases of tuberin-deficient MEFs [12] and
human tubers (shown here), the stable silencing of TSC2
expression in human BJ fibroblasts was not sufficient
Figure 6. Stable depletion of TSC2 expression in human fibroblasts
increases microtubule regrowth. (A) Human BJ fibroblasts with
stable shRNA-mediated silencing of TSC2 or expressing a control
(non-hairpin construct) were profiled for expression of TSC2, using
qRT–PCR assays. Cells silenced for TSC2 show a ∼70% reduction
in expression of this gene; error bars indicate SD (n = 3). (B)
Decreased expression of tuberin in TSC2-silenced cells relative to
control; actin served as a loading control. (C) Representative images
of microtubule regrowth in control non-hairpin and TSC2-silenced
fibroblasts are shown; scale bars= 10 μm. (D) Significant (p < 0.05)
increase in aster microtubule length revealed in fibroblasts silenced
for TSC2 expression; error bars indicate SD (n = 3)
to induce binucleated cells or disrupt nuclear envelope
morphology. This contradiction may be due to incom-
plete depletion of tuberin in TSC2-silenced BJ fibrob-
lasts (ie 60–70% depletion). In addition, it remains to
be elucidated whether similar alterations are linked to
hamartin deficiency. The previous identification of an
excess of binucleated cells and cytokinetic abnormali-
ties in hamartin-deficient cell cultures [12,24] suggests
convergence on the same mechanism.
Copyright © 2014 Pathological Society of Great Britain and Ireland. J Pathol 2014; 233: 247–257
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
Microtubule abnormalities in tuberous sclerosis lesions 255
Figure 7. The ROCK2–TPPP1–HDAC6 pathway is affected in TSC2-silenced fibroblasts. (A) Expression of ROCK2 was measured using
qRT–PCR assays from cDNA isolated from fibroblasts with stable silencing of TSC2 expression, non-hairpin control or untreated cells.
Decreased expression of ROCK2 (p < 0.05) was observed in TSC2-silenced cells compared to non-hairpin control. The expression in
non-hairpin treated control and TSC2-silenced cells was normalized to the expression of ROCK2 in untreated cells (n = 2). (B) Decreased
expression of ROCK2 in TSC2-silenced cells relative to control; actin served as a loading control. (C) Levels of acTUB were measured in
control, non-hairpin-treated and TSC2-silenced fibroblasts by immunofluorescence staining; representative images of acTUB and total
tubulin (TUBA) are shown; scale bars = 20 μm. (D) Levels of acTUB and total tubulin were analysed by confocal microscopy in untreated
(UT), control-treated and TSC2-silenced cells. The levels of acTUB were normalized to that of total tubulin, and a significant increase
was observed in TSC2-silenced cells compared to control (p < 0.05; n = 3). (E) Untreated (UT, not shown), control non-hairpin-treated
and TSC2-silenced cells were exposed to rapamycin, a specific HDAC6 inhibitor, or a vehicle (DMSO) control for 16 h and acTUB was
quantified with confocal microscopy. Relative to vehicle treatments, rapamycin treatment significantly (p < 0.05) reduced the levels of
acTUB in TSC2-silenced cells, but not in controls. Relative to vehicle treatments, treatment with the HDAC6 inhibitor significantly (p <
0.05) increased the levels of acTUB in controls, but not in TSC2-silenced cells (n = 3)
Other functions of ROCK2 include the regulation of
microtubule stability through a downstream substrate,
TPPP1. ROCK2 phosphorylates TPPP1, which prevents
the interaction between TPPP1 and HDAC6, and in turn
enables HDAC6 to deacetylate and destabilize micro-
tubules [26]. Therefore, decreased expression or activ-
ity of ROCK2 should sequester HDAC6, and elevate
microtubule acetylation in the cell. Our results in human
fibroblasts are consistent with this mechanism of action,
showing that loss of tuberin attenuated ROCK2 expres-
sion and augmented microtubule acetylation to a level
that was obtainedwithHDAC6 inhibition in parental and
control-treated cell lines. Interestingly, changes to the
ROCK2–TPPP1–HDAC6 signal transduction pathway
modulate cellular migration [26], which could provide
an explanation for the impairment of axon differentia-
tion and cell migration in tuberin-deficient mouse and rat
hippocampal neurons [8]. Together, our findings support
the hypothesis that fundamental changes in microtubule
biology underlie TSC neuropathology and highlight that
these changes may arise through the specific disruption
of ROCK2 signalling.
Acknowledgements
We wish to thank the TSC patients and their families
for their valuable participation, and the Asociación
Nacional de Esclerosis Tuberosa for their support. We
also wish to thank Aristotelis Astrinidis for scientific
discussions, Enrique Fernández-Taboada for techni-
cal assistance, and Elena Goncharova and Aristotelis
Astrinidis for providing reagents. The research was
supported by the Generalitat de Catalunya (Grant
Nos 2009-SGR283 and 2009-SGR293), Red Temática
de Investigación Colaborativa en Cáncer (Grant Nos
RD06/0020/1050 and RD12/0036/0008), the Seventh
Framework Programme of the European Commission
(Grant No. 278486, DEVELAGE), a Child and Youth
Health, New Investigator Award from the SickKids
Foundation and the Institute of Human Development
Child and Youth Health-CIHR (Grant No. NI11- 005),
a Paediatric brain tumour grant from the Michael
Cuccione Foundation for Childhood Cancer Research,
and the Spanish Ministry of Health ’Instituto de
Copyright © 2014 Pathological Society of Great Britain and Ireland. J Pathol 2014; 233: 247–257
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
256 I Ferrer et al
Salud Carlos III Fondo de Investigación Sanitaria’
(Grant Nos CA10/01474, PI10/01422, PI12/01528 and
PI13/00285).
Author contributions
IF, CAM and MAP conceived the study; PM, JC, LGB,
HC, MC, NG, HA, JJ, MS, MN, IA, AR and CL pro-
vided or prepared tissues, carried out experiments and
analysed data; and PM, CAM and MAP wrote the
manuscript. All authors had final approval of the sub-
mitted manuscript.
Abbreviations
acTUB, acetylated tubulin; GSEA, gene set expression
analysis; GO, Gene Ontology; MEFs, mouse embryonic
fibroblasts; mTOR, mechanistic target of rapamycin;
PLK1, polo-like kinase 1; pS6, phospho-Ser235-236
S6 ribosomal protein; qRT–PCR, quantitative reverse
transcription–polymerase chain reaction; ROCK2,
Rho-associated coiled-coil containing kinase 2; TACC3,
transforming acidic coiled-coil containing protein 3;
TSC, tuberous sclerosis complex; TUBA, α-tubulin;
TUBG1, γ-tubulin.
References
1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis com-
plex. N Engl J Med 2006; 355: 1345–1356.
2. Mizuguchi M, Takashima S. Neuropathology of tuberous sclerosis.
Brain Dev 2001; 23: 508–515.
3. Crino PB. The pathophysiology of tuberous sclerosis complex.
Epilepsia 2010; 51(suppl 1): 27–29.
4. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal inte-
gration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;
12: 21–35.
5. Gomez MR, Samson JR, Whittemore VH. Tuberous Sclerosis Com-
plex, 3rd edn. Oxford University Press: New York, 1999; 3–9.
6. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann NY Acad
Sci 2010; 1184: 87–105.
7. Choi YJ, Di Nardo A, Kramvis I, et al. Tuberous sclerosis complex
proteins control axon formation. Genes Dev 2008; 22: 2485–2495.
8. Magri L, Cambiaghi M, Cominelli M, et al. Sustained activation of
mTOR pathway in embryonic neural stem cells leads to development
of tuberous sclerosis complex-associated lesions. Cell Stem Cell
2011; 9: 447–462.
9. Way SW, McKenna J, 3rd, Mietzsch U, et al. Loss of Tsc2 in radial
glia models the brain pathology of tuberous sclerosis complex in the
mouse. Hum Mol Genet 2009; 18: 1252–1265.
10. Goto J, TalosDM,Klein P, et al.Regulable neural progenitor-specific
Tsc1 loss yields giant cells with organellar dysfunction in a model
of tuberous sclerosis complex. Proc Natl Acad Sci USA 2011; 108:
E1070–1079.
11. Tanwar PS, Kaneko-Tarui T, Zhang L, et al. Altered
LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption
of Sertoli cell polarity and spermatogenesis. Hum Mol Genet 2012;
21: 4394–4405.
12. Gómez-Baldó L, Schmidt S, Maxwell CA, et al. TACC3–TSC2
maintains nuclear envelope structure and controls cell division. Cell
Cycle 2010; 9: 1143–1155.
13. Astrinidis A, Senapedis W, Henske EP. Hamartin, the tuberous
sclerosis complex 1 gene product, interacts with polo-like kinase 1
in a phosphorylation-dependent manner. Hum Mol Genet 2006; 15:
287–297.
14. Bonnet CS, Aldred M, von Ruhland C, et al. Defects in cell polarity
underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet
2009; 18: 2166–2176.
15. DiBella LM, Park A, Sun Z. Zebrafish Tsc1 reveals functional
interactions between the cilium and the TOR pathway. Hum Mol
Genet 2009; 18: 595–606.
16. Hartman TR, Liu D, Zilfou JT, et al. The tuberous sclerosis proteins
regulate formation of the primary cilium via a rapamycin-insensitive
and polycystin 1-independent pathway. Hum Mol Genet 2009; 18:
151–163.
17. Chen Z, Indjeian VB, McManus M, et al. CP110, a cell
cycle-dependent CDK substrate, regulates centrosome duplication
in human cells. Dev Cell 2002; 3: 339–350.
18. Maxwell CA, Benitez J, Gómez-Baldó L, et al. Interplay between
BRCA1 and RHAMM regulates epithelial apicobasal polarization
andmay influence risk of breast cancer.PLoSBiol 2011; 9: e1001199.
19. Mohan P, Castellsague J, Jiang J, et al. Genomic imbalance of
HMMR/RHAMM regulates the sensitivity and response of malignant
peripheral nerve sheath tumour cells to aurora kinase inhibition.
Oncotarget 2013; 4: 80–93.
20. Boer K, Crino PB, Gorter JA, et al.Gene expression analysis of tuber-
ous sclerosis complex cortical tubers reveals increased expression of
adhesion and inflammatory factors. Brain Pathol 2010; 20: 704–719.
21. Blake JA, Harris MA. The Gene Ontology (GO) project: structured
vocabularies for molecular biology and their application to genome
and expression analysis. Curr Protoc Bioinformatics 2008; 7: Unit
7.2.
22. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrich-
ment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci USA 2005;
102: 15545–15550.
23. Normand G, King RW. Understanding cytokinesis failure. Adv Exp
Med Biol 2010; 676: 27–55.
24. Toyoshima M, Ohno K, Katsumoto T, et al. Cellular senescence
of angiofibroma stroma cells from patients with tuberous sclerosis.
Brain Dev 1999; 21: 184–191.
25. Doxsey S, Zimmerman W, Mikule K. Centrosome control of the cell
cycle. Trends Cell Biol 2005; 15: 303–311.
26. Schofield AV, Steel R, Bernard O. Rho-associated coiled-coil kinase
(ROCK) protein controls microtubule dynamics in a novel signal-
ing pathway that regulates cell migration. J Biol Chem 2012; 287:
43620–43629.
27. Schofield AV, Gamell C, Suryadinata R, et al. Tubulin polymeriza-
tion promoting protein 1 (Tppp1) phosphorylation by Rho-associated
coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdk1)
inhibits microtubule dynamics to increase cell proliferation. J Biol
Chem 2013; 288: 7907–7917.
28. Li J, Wang J, Jiao H, et al. Cytokinesis and cancer: Polo loves
ROCK’n’ Rho(A). J Genet Genom 2010; 37: 159–172.
29. Lowery DM, Clauser KR, Hjerrild M, et al. Proteomic screen defines
the Polo-box domain interactome and identifies Rock2 as a Plk1
substrate. EMBO J 2007; 26: 2262–2273.
30. Nogales-Cadenas R, Abascal F, Diez-Perez J, et al. CentrosomeDB:
a human centrosomal proteins database. Nucleic Acids Res 2009; 37:
D175–180.
31. Sole X, Bonifaci N, Lopez-Bigas N, et al. Biological convergence of
cancer signatures. PLoS One 2009; 4: e4544.
32. Al-Bassam J, Chang F. Regulation of microtubule dynamics by
TOG-domain proteins XMAP215/Dis1 and CLASP. Trends Cell Biol
2011; 21: 604–614.
Copyright © 2014 Pathological Society of Great Britain and Ireland. J Pathol 2014; 233: 247–257
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
Microtubule abnormalities in tuberous sclerosis lesions 257
33. Kuijpers M, Hoogenraad CC. Centrosomes, microtubules and neu-
ronal development. Mol Cell Neurosci 2011; 48: 349–358.
34. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell
behaviour. Nat Rev Mol Cell Biol 2003; 4: 446–456.
35. Lock FE, Hotchin NA. Distinct roles for ROCK1 and ROCK2 in
the regulation of keratinocyte differentiation. PLoS One 2009; 4:
e8190.
SUPPLEMENTARY MATERIAL ON THE INTERNET
The following supplementary material may be found in the online version of this article:
Figure S1. Binucleated cells and pS6 positivity in cortical tubers
Figure S2. Cytokinesis defects in cortical tubers
Figure S3. Over-expression and abnormal staining patterns of TUBG1 in tubers
Figure S4. Non-immune immunoglobulin control immunohistochemistry results
Figure S5. Under-expression of ROCK2 in tubers
Figure S6. Centrosome and nuclear envelope architecture is not altered in stable TSC2-silenced human BJ fibroblasts
Figure S7. Silencing of TSC2 expression augments microtubule regrowth dynamics in a manner that is responsive to re-expression of GFP–tuberin
Figure S8. Microtubule acetylation is responsive to changes in TSC2 expression
Table S1. Sequences of primers used in qRT–PCRs and shRNAs
Table S2. Mutational TSC1/2 status of TSC patients examined in this study
Copyright © 2014 Pathological Society of Great Britain and Ireland. J Pathol 2014; 233: 247–257
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
